Loading...
XSWXEVE
Market cap6mUSD
Dec 20, Last price  
0.81CHF
1D
-9.80%
1Q
-10.99%
Jan 2017
-99.47%
IPO
-99.97%
Name

Evolva Holding SA

Chart & Performance

D1W1MN
XSWX:EVE chart
P/E
P/S
1.41
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
18.53%
Rev. gr., 5y
-14.19%
Revenues
9m
-39.27%
0273,560164,510424,40418,926,68718,628,53011,080,2217,014,4428,706,20010,744,30013,363,6009,575,7006,846,7008,932,60011,596,0007,540,7009,877,60015,539,4009,437,800
Net income
-105m
L+142.65%
-35,042,040-72,530,960-59,120,280-66,451,549-9,608,907-23,298,866-22,451,971-16,089,948-15,731,900-21,352,900-31,891,900-35,970,700-38,976,900-29,213,900-21,638,900-29,870,200-41,266,400-43,366,400-105,229,400
CFO
-9m
L-50.98%
-34,405,780-53,947,330-59,087,490-44,535,168-5,933,657-15,831,343-17,402,435-13,445,766-12,523,800-19,943,700-31,729,200-33,852,300-35,572,900-23,607,000-14,160,500-23,362,700-29,789,200-18,880,700-9,254,500
Earnings
Mar 20, 2025

Profile

Evolva Holding SA discovers, researches, develops, and commercializes nature-based ingredients for use in flavor and fragrances, health ingredients, health protection, and other sectors in Switzerland, the United States, and internationally. It offers various ingredients comprising Veri-te Resveratrol, a nature-made polyphenol that occurs naturally in grapes and other plants, including peanuts, cranberries, and berries; L-Arabinose, a flavoring agent used in Maillard reaction; Valencene, an aroma component of citrus fruit and citrus-derived odorants; Nootkatone, an aroma ingredient of grapefruit obtained via biochemical oxidation of valencene; and Vanillin, a primary component of vanilla bean extract. The company was founded in 2004 and is headquartered in Reinach, Switzerland.
IPO date
May 04, 2005
Employees
50
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
9,438
-39.27%
15,539
57.32%
9,878
30.99%
Cost of revenue
51,386
38,898
36,870
Unusual Expense (Income)
NOPBT
(41,948)
(23,359)
(26,992)
NOPBT Margin
Operating Taxes
7,862
(141)
Tax Rate
NOPAT
(41,948)
(31,221)
(26,851)
Net income
(105,229)
142.65%
(43,366)
5.09%
(41,266)
38.15%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,046
7,352
BB yield
Debt
Debt current
12,151
7,265
Long-term debt
5,814
7,148
Deferred revenue
Other long-term liabilities
1,579
3,196
5,609
Net debt
(5,839)
10,749
1,515
Cash flow
Cash from operating activities
(9,254)
(18,881)
(29,789)
CAPEX
(2,253)
(3,784)
Cash from investing activities
15,949
(1,764)
(4,640)
Cash from financing activities
(5,973)
14,766
25,722
FCF
(19,512)
(34,400)
(36,874)
Balance
Cash
5,839
5,143
11,001
Long term investments
2,073
1,898
Excess cash
5,367
6,439
12,405
Stockholders' equity
5,570
(266,512)
(234,114)
Invested Capital
1,765
391,004
382,332
ROIC
ROCE
EV
Common stock shares outstanding
5,396
4,281
3,520
Price
Market cap
EV
EBITDA
(37,367)
(15,268)
(18,392)
EV/EBITDA
Interest
2,291
761
983
Interest/NOPBT